Female patients with AML and ALL have mutations associated with a better prognosis (FLT3-ITD, NPM1, DNMT3A in AML, and early B phenotype in ALL), while men have a higher frequency of high-risk mutations. Here, FLT3 is linked to acute myeloid leukemia.